martes, 31 de octubre de 2023

Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02296-1/fulltext?dgcid=hubspot_email_conferencealerts_esmo23&utm_campaign=conferencealerts&utm_medium=email&_hsmi=278989396&_hsenc=p2ANqtz-8bPJVar4gDxDVB8xVvEClFy1XuPwwbzZAAMrq1ejmKPgPB4gDCvfQb-eyHymUeiwwvLsQqgZ3V6xf5YW4hdJCNT-jXQQ&utm_content=278989396&utm_source=hs_email

No hay comentarios:

Publicar un comentario